Free Trial

Integra LifeSciences (IART) Stock Forecast & Price Target

$31.42
+0.05 (+0.16%)
(As of 07/24/2024 ET)

Integra LifeSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 8 Wall Street analysts who have issued ratings for Integra LifeSciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 2 have given a sell rating, 4 have given a hold rating, and 2 have given a buy rating for IART.

Consensus Price Target

$32.86
4.57% Upside
High Forecast$50.00
Average Forecast$32.86
Low Forecast$25.00

According to the 8 analysts' twelve-month price targets for Integra LifeSciences, the average price target is $32.86. The highest price target for IART is $50.00, while the lowest price target for IART is $25.00. The average price target represents a forecasted upside of 4.57% from the current price of $31.42.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$32.86$35.00$44.89$50.14
Forecasted Upside4.57% Upside21.41% Upside18.42% Upside4.25% Upside
Get Integra LifeSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

IART Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IART Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Integra LifeSciences Stock vs. The Competition

TypeIntegra LifeSciencesMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside3.58% Upside3,030.64% Upside9.80% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/16/2024Truist Financial
1 of 5 stars
 Boost TargetHold ➝ Hold$25.00 ➝ $32.00+4.92%
7/15/2024Morgan Stanley
3 of 5 stars
 Boost TargetUnderweight ➝ Underweight$24.00 ➝ $27.00-9.12%
7/10/2024Citigroup
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$28.00 ➝ $30.00+2.35%
5/7/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$49.00 ➝ $40.00+59.87%
5/7/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderperform ➝ Underperform$42.00 ➝ $26.00+12.36%
5/7/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$45.00 ➝ $25.00+8.04%
11/14/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+36.61%
7/12/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$58.00 ➝ $53.00+28.33%
6/26/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $44.00+11.25%
6/8/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
5/24/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight$56.00 ➝ $43.00+6.23%
5/23/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:00 PM ET.

IART Forecast - Frequently Asked Questions

What is Integra LifeSciences' forecast for 2024?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Integra LifeSciences is $32.86, with a high forecast of $50.00 and a low forecast of $25.00.

Should I buy or sell Integra LifeSciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.

Does Integra LifeSciences's stock price have much upside?

According to analysts, Integra LifeSciences's stock has a predicted upside of 16.50% based on their 12-month stock forecasts.

Has Integra LifeSciences been downgraded by Wall Street analysts recently?

Over the previous 90 days, Integra LifeSciences's stock had 2 downgrades by analysts.

What analysts cover Integra LifeSciences?

Integra LifeSciences has been rated by research analysts at Bank of America, Citigroup, JMP Securities, Morgan Stanley, Oppenheimer, Truist Financial, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Integra LifeSciences more than its competitors?

Analysts like Integra LifeSciences less than other "medical" companies. The consensus rating for Integra LifeSciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IART compares to other companies.


This page (NASDAQ:IART) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners